Matthew R. Janes
Discovered that a dual TORC1/2 kinase inhibitor selectively kills leukemia cells while sparing normal lymphocytes
Graduate research, UC Irvine (David A. Fruman lab) · discovery scientist, Wellspring Biosciences (2011–present; KRAS G12C drug discovery)
Wellspring Biosciences, Inc., San Diego ↗
As grad researcher, showed PP242 (dual TORC1/2 inhibitor) kills leukemia cells while sparing normal lymphocytes (JAN2010) — unlike rapamycin. Contributed to Hsieh/Ruggero's ribosome-profiling study of oncogenic mTOR in prostate cancer (HSI2012).
Moved into industry, co-author on ARS-1620 (Cell 2018), a landmark covalent KRAS-G12C inhibitor. Still active at Wellspring on KRAS-G12C programs into 2026, including combinations with mTOR/IGF1R inhibition.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2010 | M | Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor JAN2010 PP242 selectively kills leukemia cells while sparing normal lymphocytes. |
| 2012 | M | The translational landscape of mTOR signalling steers cancer initiation and metastasis HSI2012 Contributed to showing oncogenic mTOR drives prostate cancer metastasis via selective translation. |